The oral medication Amalta® (Apremilast) is a high-quality and effective solution for the treatment of psoriasis in patients aged 6 and older, psoriatic arthritis, and oral ulcers associated with Behçet’s disease. Amalta® is an efficacious and safe oral therapy that requires no routine laboratory monitoring, playing a significant role in enhancing patients’ quality of life.

Psoriasis and psoriatic arthritis are two autoimmune diseases in which the body’s immune system mistakenly attacks healthy skin and joint cells, resulting in inflammation, redness, scaling of the skin, and joint pain. Behçet’s disease is a rare multisystem inflammatory disorder that affects various parts of the body, with oral ulcers being its most common clinical manifestation.

The primary therapeutic goal in inflammatory autoimmune diseases is to control the condition, alleviate symptoms, and improve the patient’s overall quality of life. By inhibiting the activity of an enzyme known as phosphodiesterase 4 (PDE4)—which plays a crucial role in the inflammatory cascade—the oral medication Amalta® helps control patient symptoms and significantly improves their quality of life.

The oral medication Amalta® requires no baseline or ongoing laboratory testing before or during treatment, allowing patients to initiate therapy immediately following a physician’s prescription. Due to its high safety profile and optimal efficacy, Amalta® can be prescribed either as a monotherapy or in combination with other medications.

Oral Apremilast is the first and only oral treatment approved by the U.S. Food and Drug Administration (FDA) for adult patients across all severities of plaque psoriasis (mild, moderate, and severe). Furthermore, it is the only approved therapeutic option for oral ulcers associated with Behçet’s disease.

Amalta® is manufactured by Cobel Darou at Dr. Abidi Pharmaceuticals and is fully approved by the Iran Food and Drug Administration (IFDA). The oral medication Amalta® is available by prescription (Rx-only) in pharmacies nationwide.

For over 20 years, Cobel Darou has been operating in the manufacturing, importation, and distribution of pharmaceuticals in collaboration with and under the license of prominent international pharmaceutical companies. By supplying the medications needed by Iranian patients, particularly specialty drugs, the company plays a pivotal role in elevating public health standards and improving individuals’ quality of life.

IR-0227-AML-3140-PR